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Background: Insulin-like growth factor I (IGF-I), which is mostly carried in blood by IGF-binding protein 3 (IGFBP-3),
was associated to the glomerular filtration rate and chronic kidney disease in a multiethnic study among US adults.
The aim of the present study was to investigate whether serum IGF-I or IGFBP-3 are associated with estimated
glomerular filtration rate (eGFR) in a population-based study of Caucasian adults.
Methods: Data from 4028 subjects (2048 women) aged 20 to 81 years from the Study of Health in Pomerania
(SHIP) were analyzed. Total serum IGF-I and IGFBP-3 concentrations were determined by chemiluminescence
immunoassays and categorized into sex- and age-specific quartiles.
Results: After adjusting for age, waist circumference and type 2 diabetes mellitus, analysis of variance (ANOVA)
revealed inverse associations between serum IGF-I concentrations and eGFR in men as well as between serum
IGFBP-3 concentrations and eGFR in men and women. Logistic regression analyses confirmed these findings and
showed that high IGF-I or IGFBP-3 concentrations were associated with an increased risk of decreased eGFR
(<60 mL/min/1.73 m2) in men or women. These relations became stronger when lower eGFR cut-offs were used
for the analyses.
Conclusion: Our data revealed associations of increased serum IGF-I concentrations and decreased eGFR in
men but not in women and an association of increased serum IGFBP-3 concentrations and decreased eGFR in
both sexes.
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The insulin-like growth factor (IGF) system consists of
two ligands (IGF-I and IGF-II), three IGF receptors
(IGF-I receptor; IGF-II receptor; insulin receptor) and
six high-affinity IGF-binding proteins (IGFBPs; IGFBP-
1-6) [1]. IGF-I is a polypeptide with a high sequence
similarity to insulin and is mainly synthesized in the liver
upon stimulation by growth hormone (GH) [1]. In the
blood, IGF-I is mostly bound to IGF-binding protein 3* Correspondence: kathleen.dittmann@uni-greifswald.de
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reproduction in any medium, provided the or(IGFBP-3) [1]. IGF-I is involved in the regulation of
growth and cellular proliferation in humans. Furthermore,
IGF-I promotes kidney growth and increases glomerular
filtration rate (GFR) as well as renal plasma flow [2]. On
the other side, it is widely accepted that kidney disease in-
fluence the IGF/GH axis [3]. Serum IGF-I concentrations
are associated with arterial hypertension [4,5] and diabetes
mellitus [5], which in turn are known risk factors for
chronic kidney disease (CKD). With an estimated preva-
lence of 11%, CKD represents a worldwide public health
problem [4,5], which is associated with a poor quality of
life [6] and due to renal transplantation and haemodialy-
sis, with intensive costs [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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renal function yielded conflicting results [3,8-10]. Data
from patients who were investigated due to proteinuria or
haematuria or renal impairment revealed that IGF-I and
IGFBP-3 concentrations seem to be independent of renal
function [8]. In a small clinical study [3] among patients
with renal failure IGF-I was related to a reduced creatinine
clearance. A further small study [9] showed that CKD
patients had higher serum IGF-I and IGFBP-3 concen-
trations than healthy individuals suggesting a relation
between the IGF/GH axis and CKD. In the population-
based National Health and Nutrition Examination Survey
(NHANES) III study, including 5388 subjects of different
races and ethnicities, increasing serum IGF-I concentra-
tions were associated with a higher risk of CKD [10]. Clear
and strong associations between IGF-I and CKD were
observed in both sexes with the magnitude of association
being stronger in men than in women [10].
The aim of the present study was to investigate the
association between serum IGF-I or IGFBP-3 concentra-
tions and the estimated glomerular filtration rate (eGFR)
in a Caucasian population. To this end, we used data from
the Study of Health in Pomerania (SHIP), including 1980
men and 2048 women.Methods
Study population
SHIP is a population-based cohort study in West
Pomerania, a region in northeastern Germany. Details
on the SHIP design, recruitment and procedures have
been published elsewhere [11]. Baseline data collection
started in October 1997 and was finished in March 2001.
The initial sample of the baseline examination comprised
4308 (net response: 69%) participants. All participants
gave written informed consent. The study conformed to
the principles of the Declaration of Helsinki as reflected
by an a priori approval of the Ethics Committee of the
University of Greifswald.
Of the 4308 participants, 243 subjects with missing
values for serum IGF-I, IGFBP-3 or creatinine concentra-
tions were excluded. Furthermore, we excluded one
subject with disease of pituitary gland, currently pregnant
women and women with uncertainty of current pregnancy
(n = 20) and subjects with missing data for selected
confounding factors (n = 16). Altogether, the final study
population for the present analyses included 4028 subjects
(1980 men; 2048 women) aged 20 to 81 years.Data collection
Information on age, sex, sociodemographic characteristics
and medical histories were assessed by computer- assisted
personal interviews. Smoking status was assessed by self-report and categorized in current smoker and non-
smoker. Subjects who participated in physical training
during summer or winter for at least 1 h a week were
classified as being physically active. The definition of type
2 diabetes mellitus was based on self-reported physician’s
diagnosis or self-reported use of antidiabetic medication
[anatomic, therapeutic, and chemical (ATC) code: A10]
during the last 7 days. Hypertension was defined as
systolic blood pressure ≥140 mmHg and/or diastolic blood
pressure ≥90 mmHg or the self-reported use of antihyper-
tensive medication. Waist circumference (WC) was mea-
sured to the nearest 0.1 cm using an inelastic tape midway
between the lower rib margin and the iliac crest in the
horizontal plane, with the subject standing comfortably
with weight distributed evenly on both feet.
Non-fasting blood samples were analyzed immediately
or stored at −80°C. Serum creatinine concentrations were
determined with the Jaffé method (Hitachi 717; Roche
Diagnostics, Mannheim, Germany). The four-variable
Modification of Diet in Renal Disease (MDRD) study
equation was used for calculation of the eGFR from serum
creatinine [eGFR [mL/min/1.73 m2] = 186.3 * serum cre-
atinine [mg/dL]-1.154 * age [years]-0.203 * (0.742 if female)]
[12,13]. CKD was defined as an eGFR <60 mL/min/
1.73 m2, consistent with the definition by National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(KDOQI) of CKD ≥ stage 3 [13].
Total serum IGF-I and IGFBP-3 concentrations
were determined by automated two-site chemilumin-
escence immunoassay (Nichols Advantage; Nichols
Institute Diagnostica GmbH, Bad Vilbel, Germany). In
both assays, biotin-labeled monoclonal antibodies were
used as capture, and in a second step acridinium-ester-
labeled monoclonal antibodies were used for detection.
To determine IGF-I concentration, the samples under-
went preanalytical acidification to separate IGF-I from
IGFBPs. The analytical sensitivity was 6 ng/mL, the
intraassay imprecision within the range of 63–766 ng/mL
was 4.8% and interassay imprecision within the range of
62–811 ng/mL was 6.7%. The IGF-I assay was calibrated
against the World Health Organization International
Reference Reagent 1988, IGF-I 87/518. The analytical
sensitivity of the IGFBP-3 assay was 20 ng/mL, the
intra- and interassay imprecision within the range of
227–2703 ng/mL were 5.8 and 11%, respectively. The
assay reference standard was analytically prepared
with glycosylated recombinant human IGFBP-3. Only
one lot of reagents was used for all IGFBP-3 mea-
surements. Established reference values in SHIP have
been shown elsewhere [14]. Serum IGF-I and IGFBP-3
concentrations were either used as continuous parameters
or were categorized into four groups according to the
sex- and age-specific quartiles of distribution Additional
file 1: Table S1.
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Continuous data are expressed as median (25th; 75th
quartile); nominal data are expressed as percentage. For
bivariate comparisons between women and men the
Kruskal-Wallis test (continuous data) or the χ2-test (nom-
inal data) were used. Analysis of variance (ANOVA) or
logistic regression models adjusted for age, waist circum-
ference and type 2 diabetes mellitus were performed to
assess the associations between serum IGF-I or IGFBP-3
concentrations and eGFR. Adjusted means and odds ratios
(ORs) with 95% confidence intervals (CIs) were calculated.
Analyses were performed for the whole cohort and separ-
ately for men and women. Additional analyses were
performed by using different cut-offs for eGFR (50, 55,
and 65 mL/min/1.73 m2, respectively). In sensitivity
analyses all models were repeated with hypertension as
confounder or after the exclusion of subjects with type 2
diabetes mellitus. A p-value < 0.05 was considered statisti-
cally significant. Statistical analyses were performed with
SAS 9.2 (SAS Institute Inc., Cary, NC).
Results
The baseline characteristics of our study population
demonstrated that men were older, more often smokers,
more often affected by hypertension and had lower
serum IGFBP-3 concentrations than women (Table 1).
Regarding kidney function, men had a higher eGFR and
were less often affected by CKD, albeit they had higher
serum creatinine concentrations than women.
Multivariable ANOVA revealed inverse associations
between serum IGF-I or IGFBP-3 and eGFR in men and
an inverse association between serum IGF-I and eGFR in
women (Figure 1). In detail, in men the eGFR decreased
with respect to serum IGF-I concentrations up to 4.9 mL/Table 1 Characteristics of the study population
Characteristics Men
(n = 1980)
Age (years) 52 (37; 65)
Waist circumference (cm) 95.2 (87.5; 103.0)
Physical activity (%) 41.5
Current smoker (%) 33.2
Type 2 diabetes mellitus (%) 8.7
Hypertension (%) 62.7
Serum IGF-I (ng/mL) 131 (103; 168)
Serum IGFBP-3 (ng/mL) 1795 (1473; 2110)
Serum creatinine (mg/dL) 1.02 (0.94; 1.12)
eGFR (mL/min/1.73m2) 83.02 (73.54; 92.97)
CKD (%) 6.6
Continuous data are given as median (25th; 75th quartile); nominal data are given
IGF-I = insulin-like growth factor I; IGFBP-3 = insulin-like growth factor-binding prote
defined as eGFR < 60 ml/min/1.73 m2.min/1.73 m2 and with respect to serum IGFBP-3 con-
centrations up to 3.7 ml/min/1.73 m2 from the lowest to
the highest exposure group. In women the eGFR de-
creased up to 1.3 ml/min/1.73 m2 from the lowest to the
highest IGF-I group.
To clarify the association between IGF-I or IGFBP-3
and renal dysfunction we used logistic regression models
adjusted for age, waist circumference and type 2 diabetes
mellitus. Using serum IGF-I or IGFBP-3 concentrations as
continuous variables, we observed non-significant associa-
tions between increasing concentrations of IGF-I (men:
OR for one standard deviation (SD) increase 1.2 [95% CI
0.95-1.50]; women: OR 0.97 [95% CI 0.80-1.19]) or
IGFBP-3 (men: OR 1.13 [95% CI 0.93-1.38]; women: OR
1.11 [95% CI 0.96-1.29]) and CKD (Figure 2). However, by
varying the cut-off to define low eGFR (<50, <55, <60, <65
mL/min/1.73 m2), we observed that the relation between
serum IGF-I or IGFBP-3 concentrations and eGFR be-
came significant when lower cut-offs were used in both
sexes. In detail, the odds for having an eGFR <50 mL/
min/1.73 m2 increased with rising IGF-I levels (men: OR
per SD increase 1.76 [95% CI 1.27-2.45]; women: 1.27
[95% CI 0.90-1.80]) or IGFBP-3 levels (men: OR per SD
increase 1.48 [95% CI 1.06-2.07]; women 1.33 [95% CI
1.01-1.77]).
Our main results were confirmed in sensitivity analyses
with hypertension (n = 2095) as confounder or after exclu-
sion of all subjects with type 2 diabetes mellitus (n = 323)
(data not shown).
Discussion
In the present study, we observed an association between
increased serum IGF-I and decreased eGFR in men but
not in women and between increased serum IGFBP-3Women p
(n = 2048)
49 (36; 62) <0.01





134 (101; 172) 0.36
1971 (1666; 2279) <0.01
0.87 (0.80; 0.94) <0.01
74.84 (66.83; 84.51) <0.01
11.1 <0.01
as percentages. χ2-test (nominal data) or Kruskal-Wallis test (interval data).
in 3; eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease
Figure 1 Mean estimated glomerular filtration rate (eGFR) with 95% confidence interval by (A) insulin-like growth factor I (IGF-I) and
(B) IGF-binding protein 3 (IGFBP-3) quartiles in men (black square) and women (white square). Analyses of variance were adjusted for age,
waist circumference and type 2 diabetes mellitus.
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findings regarding IGF-I confirm the data from the
NHANES III study [10] revealing a positive association
between serum IGF-I concentrations and risk of CKD.
A study in monozygotic and dizygotic adults twin pairs
of the same sex showed that women had higher serum
IGFBP-3 concentrations than men [15]. Furthermore,
sex-specific differences in serum IGF-I concentrations
were detected and showed that the median serum IGF-I
value was 3 ng/mL lower in women compared to men
[14,15]. The differences in serum IGF-I or IGFBP-3
concentrations between men and women justify perform-
ing sex-segregated analysis tests and may explain the
slightly different results with respect to the association
between IGF-I and CKD in the present study. However,
the positive association between increased serum IGF-I
and decreased eGFR only barely missed statistical signifi-
cance in women. The same trend was observed in
NHANES III [10].
In comparison to our results, a small Danish study
found lower free serum IGF-I and higher serum IGFBP-
3 concentrations in patients with CKD compared to
healthy controls [3]. However, total IGF-I concentrations
were slightly but not significantly increased in patients
with CKD compared to healthy controls. PeritonealFigure 2 Odds ratio (OR) with 95% confidence interval for renal dysfu
rate (eGFR) by 1 standard deviation increase in insulin-like growth fa
f) = number of participants (m =male; f = female). Logistic regression analys
mellitus.dialysis and haemodialysis patients had significantly
higher serum IGF-I and IGFBP-3 concentrations than
subjects with normal renal function [16]. Another study
[17] showed normal serum IGF-I concentrations, but
elevated serum IGFBP-3 concentrations in patients with
CKD and different types of renal osteodystrophy com-
pared to healthy control subjects. Taking into account
the decreased renal clearance and thus an increased
half-life of IGF-I in CKD [18], elevated serum IGF-I con-
centrations may be expected and normal serum IGF-I
concentrations may indicate reduced production. In
advanced renal failure, other condition such as metabolic
acidosis has been shown to reduce serum IGF-I concen-
trations [19]. The altered metabolic milieu in severe
CKD affects the secretion of hormones and the hormone-
induced response of target tissues, causing endocrine
dysfunctions [20].
A further study among 500 never-treated hypertensive
patients [4] showed an positively and strong association
between IGF-I and eGFR which is in contrast to our
results even if we have a high proportion of subjects
with hypertension. Possible reason for this discrepancy
might be that compared to the never-treated hyperten-
sive subjects investigated by Peticone et al. [4] the large
part of our participants with hypertension (44.9%) werenction using different cut-offs for estimated glomerular filtration
ctor 1 (A) and IGF binding protein 3 (B) in men and women. N (m/
es were adjusted for age, waist circumference and type 2 diabetes
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renal function and cardiovascular mortality even in
non-dialysis-dependent CKD [21], which was confirmed
by a recent large meta-analysis of 21 general population
cohorts [22]. This association might be modulated by
different IGF-I serum concentrations. In previous epi-
demiological studies IGF-I, as well as IGFBP-3, has been
suggested as risk factor for all-cause and cardiovascular
mortality [23]. In a recent meta-analysis [24] low, as well
as high, IGF-I serum concentrations were associated
with increased mortality in the general population. Thus,
in early or moderate renal failure, serum IGF-I concen-
trations may be elevated due to increased IGF-I half-life
and may become clinically relevant in later stages of
renal failure. Nevertheless, we assume that the IGF/GH
axis is a biomarker rather than a risk factor for renal
diseases and reflects the healthy status which might also
be influenced by renal disorders. Therefore, IGF-I is not
specific for impaired renal function.
IGFBP-3 is specifically cleaved by proteases and low-
molecular weight IGFBP-3 fragments accumulating in
CKD may be detected by the usual radioimmunoassay. In
an earlier study in CKD patients, the intact serum IGFBP-3
concentrations stayed within normal limits [25].
The key strength of our study is the large population-
based sample of 4028 men and women aged 20–81 years.
A further strength is the high grade of quality assurance of
the laboratory method. All assays were performed on a
single analyzer using the same reagents and were con-
ducted by skilled technicians and, therefore, minimizing
analytical variability. However, a limitation of our study
arise from the cross-sectional design that is generally not
suitable to prove causal relations. Furthermore, no mea-
surements of free IGF-I or IGF-II were available which
would provide a more complete view on the relation
between the IGF/GH axis and renal function.
Conclusion
In conclusion, we found an association of increased serum
IGFBP-3 concentrations with decreased eGFR in both
sexes and an association of increased serum IGF-I concen-
trations and decreased eGFR in men but not in women.
Additional file
Additional file 1: Table S1. Serum IGF-I and IGFBP-3 distribution by sex
and age-group.
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